Here we present structural and dynamic studies of MBD4MBD bound to dsDNA.
2
Both charges and reimbursements were also significantly greater in the MBD cohort.
3
Conclusion: We identified several CKD-MBD phenotypes associated with reduced hospitalization-free survival and increased mortality.
4
Urinary isolated susceptibility testing was done by micro broth dilution (MBD).
5
This model could aid in the development of Endo180 targeted therapies for MBD in the future.
6
A case-control study comparing PFF in patients with and without MBD treated with HA was performed.
7
Areas covered: This review discusses the advantages and disadvantages of the above pharmacological options to treat CKD-MBD.
8
Conclusions: Taken together, our results confirm that the current CKD-MBD therapies have an effect on serum levels of FGF23.
9
We tested the association between CKD-MBD phenotypes and 5-year mortality and hospitalization risk by outcome risk score-adjusted proportional hazard regression.
10
Results: Patients treated with HA for fractures with MBD have higher rates of medical complications compared to fracture patients without MBD.
11
It has also been used to treat fractures of the proximal femur in patients with metastatic bone disease (MBD).
12
Evercore Partners and Peel Hunt advised Hastings on the deal while Goldman Sachs International acted as financial adviser to GS MBD.
13
In this case report we present the MR imaging findings of MBD and review of the other imaging features of the disease.
14
Evercore Partners EVR.N and Peel Hunt advised Hastings on the deal while Goldman Sachs International acted as financial adviser to GS MBD.
15
Expert opinion: The individual-based use of phosphate binders, vitamin D and calcimimetics, separately or in combination, constitute a reasonable approach to treat CKD-MBD.
16
The pathogenesis and clinical manifestations of these components of CKD-MBD are described in detail in this issue of Advances in Chronic Kidney Disease.